Grant ID DP180042
Awarded On August 24, 2018
Title Combination Drug Therapy for Cutaneous T-Cell Lymphoma
Program Product Development Research
Award Mechanism Texas Company Product Development Awards
Institution/Organization CerRx, Inc.
Principal Investigator/Program Director Kerry Barnhart
Cancer Sites Lymphoma
Contracted Amount $11,783,916*

*Pending contract negotiation

Lay Summary

CerRx, Inc. is a west Texas-based company developing a new drug for treating cancer with better effectiveness and fewer side-effects than current treatments. CerRx’s lead drug candidate, intravenous (IV) fenretinide, has been shown in human clinical trials to be particularly effective in treating T-cell lymphomas (in some cases completely abolishing the cancers), while having fewer side-effects than other drug used for treating such tumors. CerRx has one currently open clinical trial to further test IV fenretinide on one type of T-cell lymphoma, peripheral T-cell lymphoma (PTCL), a cancer than can case tumors to form anywhere in the body.

CerRx is now proposing to conduct a similar clinical t...

Read More